EUCTR2010-020724-21-AT进行中（未招募）1 期
Amyloid Imaging with [11C]PIB PET and MRI in MCI – a pilot study - MCI and PIB
niversitätsklinik für Neurologie, Medizinische Universität Wien0 个研究点开始时间: 2011年2月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age range between 60-80 years, male and female
- •Neuropsychological Testing with diagnosis of Mild Cognitive impairment – amnestic or non amnestic type (single and multiple domain).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •major life threatening internal diseases, for example heart failure, cancer, ..
- •major neurological diseases except MCI, for example major stroke, parkinsonism
- •major psychiatric diseases except dementia, for example major depression
研究者
相似试验
已完成
不适用
PET Imaging of Brain Amyloid Using 11C-PIB in Neurological DiseasesAlzheimer's disease Neurodegenerative diseasesJPRN-UMIN000004195Human Brain Research Center, Kyoto University Graduate School of Medicine50
尚未招募
不适用
Research for Amyloid PET-MRIHealthy volunteer, Alzheimer's disease, Mild cognitive impairment, Parkinson's disease, PDJPRN-UMIN000040338Kyoto University160
Enrolling By Invitation
4 期
Imaging of Brain Amyloid Plaques in the Aging PopulationDementia With Lewy BodiesAlzheimer's DiseaseVascular DementiaFrontotemporal DementiaNCT00950430Mayo Clinic8,000
已完成
不适用
Amyloid PET imaging study for dimenting disordersdementing disorderJPRN-UMIN000028758Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama20
进行中（未招募）
1 期
oneFocal dementia syndromes - primary aphasiaMedDRA version: 14.1 Level: LLT Classification code 10012292 Term: Dementia of the Alzheimer's type NOS System Organ Class: 10029205 - Nervous system disordersEUCTR2010-023852-10-GBAvid Radiopharmaceuticals, Inc.23